0001144204-17-040438.txt : 20170804 0001144204-17-040438.hdr.sgml : 20170804 20170804080018 ACCESSION NUMBER: 0001144204-17-040438 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 EFFECTIVENESS DATE: 20170804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 171006916 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 25 1 v472247_form25.htm FORM 25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number

001-32715

 

 

Interleukin Genetics, Inc.

OTCQB

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

 

135 Beaver Street

Waltham, MA 02452

(781) 398-0700

 

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

 

All authorized Preferred and Common stock

 

(Description of class of securities)

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

¨17 CFR 240.12d2-2(a)(1)
  
¨17 CFR 240.12d2-2(a)(2)
  
¨17 CFR 240.12d2-2(a)(3)
  
¨17 CFR 240.12d2-2(a)(4)
  
¨Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
  
xPursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

 

1Form 25 and attached notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Interleukin Genetics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

Date:  August 4, 2017   By:   /s/ Barry Kallander  
    Title President